ReviewTargeted oncology2024
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
Review in Targeted oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Immune crosstalk in metabolic dysfunction-associated steatotic liver disease: interactions between innate and adaptive immunity.Frontiers in immunology · 2026Review
- Immune checkpoint biology in hepatocellular carcinoma (Review).Oncology letters · 2025Review
- Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).Journal of clinical and translational hepatology · 2025Article
- Predicting the occurrence of liver injury induced by immune checkpoint inhibitors in hepatocellular carcinoma patients: a retrospective analysis.BMC cancer · 2025Article
- Integrating ultrasound and serum indicators for evaluating outcomes of targeted immunotherapy in advanced liver cancer.World journal of gastrointestinal oncology · 2025Article
- Boosting cancer immunotherapy: drug delivery systems leveraging ferroptosis and immune checkpoint blockade.Frontiers in immunology · 2025Review
- A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving durvalumab in combination with tremelimumab.Frontiers in immunology · 2025Article
- [Consensus on the management of liver injury associated with targeted drugs and immune checkpoint inhibitors for hepatocellular carcinoma ( version 2024)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Current Treatment Methods in Hepatocellular Carcinoma.Cancers · 2024Review
- Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review.Ewha medical journal · 2024Review
- Review
- Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments-An Overview.Biomolecules · 2024Review
- Orbital Metastasis as the First Manifestation of Hepatocellular Carcinoma, and Its Effective Treatment with Combined Dual Immunotherapy: A Case Report and Review of the Literature.The American journal of case reports · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tremelimumab (tremelimumab-actl; Imjudo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.